Skip to content

Study · Non-randomized trial · 2016

6 results

Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme.

Yu M, Van Brunt K, Varnado OJ, Boye KS

Diabetes, obesity & metabolism4 Feb 2016Cited by 26 (Europe PMC)

PMID26691396 (opens in a new tab)DOI10.1111/dom.12624 (opens in a new tab)PepBankPUB-26691396
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In T2D patients, dulaglutide 1.5 mg improved IW-SP scores significantly more than insulin glargine.

    In plain wordsIn people with diabetes, dulaglutide 1.5 mg improved weight self-perception more than insulin glargine.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Direction not reportedWeight self-perception
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Quality of life · Whole body
    Studied dose
    1.5 mgAs given in this study (human).

    Source sentences

    Summary
    Compared with insulin glargine, significantly greater improvements in the IW-SP score were observed with dulaglutide 1.5 mg and with both dulaglutide doses in the APPADL score.
    1 context sentence
    Summary · context
    We evaluated patient-reported outcome (PRO) measures from the Assessment of Weekly AdministRation of LY2189265 (dulaglutide) in Diabetes (AWARD) clinical trial programme for dulaglutide (1.5 mg and 0.75 mg) in patients with type 2 diabetes (T2D).
  2. 02HumanNon-randomized trialEfficacy outcome

    In T2D patients, dulaglutide 1.5 mg improved APPADL scores significantly more than insulin glargine.

    In plain wordsIn people with diabetes, dulaglutide 1.5 mg improved weight-related daily activity scores more than insulin glargine.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Direction not reportedWeight-related physical activities
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Quality of life · Whole body
    Studied dose
    1.5 mgAs given in this study (human).

    Source sentences

    Summary
    Compared with insulin glargine, significantly greater improvements in the IW-SP score were observed with dulaglutide 1.5 mg and with both dulaglutide doses in the APPADL score.
    1 context sentence
    Summary · context
    We evaluated patient-reported outcome (PRO) measures from the Assessment of Weekly AdministRation of LY2189265 (dulaglutide) in Diabetes (AWARD) clinical trial programme for dulaglutide (1.5 mg and 0.75 mg) in patients with type 2 diabetes (T2D).
  3. 03HumanNon-randomized trialEfficacy outcome

    In T2D patients, dulaglutide 0.75 mg improved APPADL scores significantly more than insulin glargine.

    In plain wordsIn people with diabetes, dulaglutide 0.75 mg improved weight-related daily activity scores more than insulin glargine.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Direction not reportedWeight-related physical activities
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Quality of life · Whole body
    Studied dose
    0.75 mgAs given in this study (human).

    Source sentences

    Summary
    Compared with insulin glargine, significantly greater improvements in the IW-SP score were observed with dulaglutide 1.5 mg and with both dulaglutide doses in the APPADL score.
    1 context sentence
    Summary · context
    We evaluated patient-reported outcome (PRO) measures from the Assessment of Weekly AdministRation of LY2189265 (dulaglutide) in Diabetes (AWARD) clinical trial programme for dulaglutide (1.5 mg and 0.75 mg) in patients with type 2 diabetes (T2D).
  4. 04HumanNon-randomized trialEfficacy outcome

    In T2D patients, dulaglutide 1.5 mg improved all DTSQ subscales significantly more than exenatide.

    In plain wordsIn people with diabetes, dulaglutide 1.5 mg improved all treatment-satisfaction subscales more than exenatide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Direction not reportedTreatment satisfaction, all subscales
    Study

    n: not reported in source

    Comparator
    Exenatide
    Outcome group
    Quality of life · Whole body
    Studied dose
    1.5 mgAs given in this study (human).

    Source sentences

    Summary
    Both dulaglutide doses resulted in significantly greater improvement in DTSQ scores (all subscales) compared with exenatide.
    1 context sentence
    Summary · context
    We evaluated patient-reported outcome (PRO) measures from the Assessment of Weekly AdministRation of LY2189265 (dulaglutide) in Diabetes (AWARD) clinical trial programme for dulaglutide (1.5 mg and 0.75 mg) in patients with type 2 diabetes (T2D).
  5. 05HumanNon-randomized trialEfficacy outcome

    In T2D patients, dulaglutide 0.75 mg improved all DTSQ subscales significantly more than exenatide.

    In plain wordsIn people with diabetes, dulaglutide 0.75 mg improved all treatment-satisfaction subscales more than exenatide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Direction not reportedTreatment satisfaction, all subscales
    Study

    n: not reported in source

    Comparator
    Exenatide
    Outcome group
    Quality of life · Whole body
    Studied dose
    0.75 mgAs given in this study (human).

    Source sentences

    Summary
    Both dulaglutide doses resulted in significantly greater improvement in DTSQ scores (all subscales) compared with exenatide.
    1 context sentence
    Summary · context
    We evaluated patient-reported outcome (PRO) measures from the Assessment of Weekly AdministRation of LY2189265 (dulaglutide) in Diabetes (AWARD) clinical trial programme for dulaglutide (1.5 mg and 0.75 mg) in patients with type 2 diabetes (T2D).
  6. 06HumanNon-randomized trialEfficacy outcome

    In T2D patients, dulaglutide 1.5 mg improved the DTSQ hyperglycaemia subscale significantly more than metformin.

    In plain wordsIn people with diabetes, dulaglutide 1.5 mg improved the high-blood-sugar questionnaire score more than metformin.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Direction not reportedDTSQ hyperglycaemia subscale
    Study

    n: not reported in source

    Comparator
    Metformin
    Outcome group
    Quality of life · Whole body
    Studied dose
    1.5 mgAs given in this study (human).

    Source sentences

    Summary
    Dulaglutide 1.5 mg also resulted in significantly greater improvement on the DTSQ hyperglycaemia subscale compared with metformin.
    1 context sentence
    Summary · context
    We evaluated patient-reported outcome (PRO) measures from the Assessment of Weekly AdministRation of LY2189265 (dulaglutide) in Diabetes (AWARD) clinical trial programme for dulaglutide (1.5 mg and 0.75 mg) in patients with type 2 diabetes (T2D).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials6

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

6 trials · 6 completed · 6 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01624259

A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes

Eli Lilly and Companyn = 599Jun 2012 to Nov 2013

Type 2 Diabetes

Trial pageClinicalTrials.govUpdated 9 Oct 2014
CompletedPhase 3Results postedNCT01191268

A Study in Participants With Type 2 Diabetes Mellitus (AWARD-4)

Eli Lilly and Companyn = 884Nov 2010 to Sept 2012

Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 8 Oct 2014
CompletedPhase 3Results postedNCT01126580

A Study in Participants With Type 2 Diabetes Mellitus (AWARD-3)

Eli Lilly and Companyn = 807May 2010 to Jun 2012

Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 16 Jan 2015
CompletedPhase 3Results postedNCT01064687

A Study in Participants With Type 2 Diabetes Mellitus

Eli Lilly and Companyn = 978Feb 2010 to May 2012

Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 26 Jan 2015
CompletedPhase 3Results postedNCT01075282

A Study in Participants With Type 2 Diabetes Mellitus (AWARD-2)

Eli Lilly and Companyn = 810Feb 2010 to Nov 2012

Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 16 Jan 2015
CompletedPhase 2/3Results postedNCT00734474

A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin

Eli Lilly and Companyn = 1,202Aug 2008 to Jul 2012

Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 20 Apr 2015

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.